Dextromethorphan hydrobromide
Biological Activity
Non-competitive, low affinity NMDA receptor antagonist. Antitussive, anticonvulsive and neuroprotective agent.
Technical Data
| M. Wt | 352.31 |
| Formula | C18H25NO.HBr |
| Storage | Store at RT |
| Purity | ≥99% (HPLC) |
| CAS Number | 6700-34-1 |
| PubChem ID | 5464025 |
| InChI Key | MISZALMBODQYFT-URVXVIKDSA-N |
| Smiles | [H][C@@]12[C@@H]4CC(C=CC(OC)=C3)=C3[C@@](CCN4C)1CCCC2.Br |
The technical data provided above is for guidance only. For batch specific data refer to the Certificate of Analysis.
All Tocris products are intended for laboratory research use only.
Solubility Data
| Solvent | Max Conc. mg/mL | Max Conc. mM | |
|---|---|---|---|
| Solubility | |||
| water | 14.09 | 40 |
Preparing Stock Solutions
The following data is based on the product molecular weight 352.31. Batch specific molecular weights may vary from batch to batch due to solvent of hydration, which will affect the solvent volumes required to prepare stock solutions.
| Concentration / Solvent Volume / Mass | 1 mg | 5 mg | 10 mg |
|---|---|---|---|
| 1 mM | 2.84 mL | 14.19 mL | 28.38 mL |
| 5 mM | 0.57 mL | 2.84 mL | 5.68 mL |
| 10 mM | 0.28 mL | 1.42 mL | 2.84 mL |
| 50 mM | 0.06 mL | 0.28 mL | 0.57 mL |
Molarity Calculator
Reconstitution Calculator
Dilution Calculator
Product Datasheets
References
References are publications that support the biological activity of the product.
Choi et al (1987) Dextrorophan and levorphanol selectively block N-methyl-D-aspartate receptor-mediated neurotoxicity on corticol neurons. J.Pharmacol.Exp.Ther. 242 713 PMID: 3039122
Keller et al (2008) Dextromethorphan is protective against sensitized N-methyl-D-aspartate receptor-mediated excitotoxic brain damage in the developing mouse brain. Eur.J.Neurosci. 27 874 PMID: 18279363
If you know of a relevant reference for Dextromethorphan hydrobromide, please let us know.
View Related Products by Target
View Related Products by Product Action
Keywords: Dextromethorphan hydrobromide, Dextromethorphan hydrobromide supplier, NMDA, receptor, antagonists, Glutamate, Receptors, N-Methyl-D-Aspartate, iGluR, Ionotropic, 3071, Tocris Bioscience
1 Citation for Dextromethorphan hydrobromide
Citations are publications that use Tocris products. Selected citations for Dextromethorphan hydrobromide include:
Ghoshooni et al (2011) Milled Stress Reduces Morphine-Induced Locomotion in F2 NMRI Mice. Pharmacol Res Perspect 10 347 PMID: 24250364
Do you know of a great paper that uses Dextromethorphan hydrobromide from Tocris? Please let us know.
Reviews for Dextromethorphan hydrobromide
There are currently no reviews for this product. Be the first to review Dextromethorphan hydrobromide and earn rewards!
Have you used Dextromethorphan hydrobromide?
Submit a review and receive an Amazon gift card.
$10US/$10CAN/€7/£6 gift card for a review without an image
$25US/$25CAN/€18/£15 gift card for a review with an image
*Offer only valid in the USA / Canada, UK and Europe
Submit a ReviewLiterature in this Area
Tocris offers the following scientific literature in this area to showcase our products. We invite you to request* or download your copy today!
*Please note that Tocris will only send literature to established scientific business / institute addresses.
Neurodegeneration Product Guide
A collection of over 275 products for neurodegeneration research, the guide includes research tools for the study of:
- Alzheimer's disease
- Parkinson's disease
- Huntington's disease
Pain Research Product Guide
A collection of over 250 products for pain research, the guide includes research tools for the study of:
- Nociception
- Ion Channels
- G-Protein-Coupled Receptors
- Intracellular Signaling
Alzheimer's Poster
Alzheimer's disease (AD) is a degenerative brain disease and the most common cause of dementia, affecting approximately 47 million people worldwide. Updated in 2015, this poster summarizes the structural and functional changes observed in the progression of this neurodegenerative disease, as well as classic AD drug targets.
Depression Poster
Major depressive disorder is characterized by depressed mood and a loss of interest and/or pleasure. Updated in 2015 this poster highlights presynaptic and postsynaptic targets for the potential treatment of major depressive disorder, as well as outlining the pharmacology of currently approved antidepressant drugs.
Huntington's Disease Poster
Huntington's disease (HD) is a monogenic neurodegenerative disorder, which is characterized by the prevalent loss of GABAergic medium spiny neurons (MSN) in the striatum. This poster summarizes the MSN intracellular signaling pathways implicated in the pathology of HD, as well as highlighting the use of iPSCs for HD modeling.
Learning & Memory Poster
Recognition memory enables us to make judgements about whether or not we have encountered a particular stimulus before. This poster outlines the cellular mechanisms underlying recognition memory and its links to long-term depression, as well as the use of pharmacological intervention to assess the role of neurotransmitters in recognition memory.
Pain Poster
Peripheral sensitization is the reduction in the threshold of excitability of sensory neurons that results in an augmented response to a given external stimulus. This poster outlines the excitatory and inhibitory signaling pathways involved in modulation of peripheral sensitization. The role of ion channels, GPCRs, neurotrophins, and cytokines in sensory neurons are also described.
Parkinson's Poster
Parkinson's disease (PD) causes chronic disability and is the second most common neurodegenerative condition. This poster outlines the neurobiology of the disease, as well as highlighting current therapeutic treatments for symptomatic PD, and emerging therapeutic strategies to delay PD onset and progression.
Schizophrenia Poster
Schizophrenia is a debilitating psychiatric disorder that affects 1% of the worldwide population. This poster describes the neurobiology of Schizophrenia, as well as highlighting the genetic and environmental factors that play a fundamental role in the etiology of the disease. The current and emerging drug targets are also discussed.
